CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and our CRO’s are focused on completing enrollment of both of our Phase 3 MAESTRO clinical trials as rapidly as possible,” said Becky Taub, M.D., […]
Other News
Silk Road Medical Reports Second Quarter 2020 Financial Results
SUNNYVALE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2020. “While the second quarter posed several challenges, we are pleased with […]
ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board
Westport, CT, Aug. 05, 2020 (GLOBE NEWSWIRE) — Dr. Sofia is an Inductee in the American Chemical Society Medicinal Chemistry Hall of Fame ViralClear Pharmaceuticals is Currently in Phase 2 Trials with Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), […]
Stereotaxis Reports 2020 Second Quarter Financial Results
ST. LOUIS, Aug. 06, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2020. “Stereotaxis responded to the challenges of COVID-19 with resilience, prudence and creativity. Despite a 21% year-over-year […]
TransMedics Reports Second Quarter 2020 Financial Results
ANDOVER, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended June 30, 2020. Recent Highlights OCS Heart FDA Advisory […]
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseases ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020 WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a […]
Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter
– Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, topline data expected Q4 2020 – Progressing first- or best-in-class drug candidates with liquidity position of ~$1.3bn as of June 30, 2020 SAN DIEGO, Aug. 5, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial […]
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney disease on dialysis Maintains strong balance sheet with $204.8 million in cash, cash equivalents and short-term investments FREMONT, Calif., Aug. […]
CorMatrix® Cardiovascular, Inc. Receives European Community and U.S. Patent Claim Allowances for Polymer Drug Delivery Prostheses
ATLANTA, Aug. 5, 2020 /PRNewswire/ — CorMatrix® Cardiovascular, Inc., (www.cormatrix.com) a leading developer of regenerative biomaterial compositions and medical devices, today announced European Patent Office patent claim allowances for European Community (EC) Patent Application Nos. 15 902 462.9 and 15 886 687.1, and U.S. Patent and Trademark Office patent claim allowance for U.S. Patent […]
Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure
– INXN-4001 delivered via retrograde coronary sinus infusion was well-tolerated in patients with chronic heart failure – – Preliminary data suggest an overall improvement in patient reported outcomes in 50% of patients six months after treatment – GERMANTOWN, Md., Aug. 6, 2020 /PRNewswire/ — Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company […]
Recent
New Study Highlights Safety and Efficacy Profile of Haemonetics’ VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)
Reflow Medical Announces U.S. Launch of Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters
Popular
- No commented posts yet